Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Britton Boras

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|December 5, 2025
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 InhibitorGary M Gallego, Cynthia Palmer, Suvi Orr, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Science Advances|August 30, 2024
Discovery of SARS-CoV-2 papain-like protease (PL<sup>pro</sup>) inhibitors with efficacy in a murine infection modelMichelle R Garnsey, Matthew C Robinson, Luong T Nguyen, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications|October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|December 5, 2025
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 InhibitorGary M Gallego, Cynthia Palmer, Suvi Orr, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Science Advances|August 30, 2024
Discovery of SARS-CoV-2 papain-like protease (PL<sup>pro</sup>) inhibitors with efficacy in a murine infection modelMichelle R Garnsey, Matthew C Robinson, Luong T Nguyen, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications|October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 2